Matt is committed to the development and commercialization of innovative therapies for rare and hard to treat neurological diseases Matt has spent more than 5 years at Biogen now. Since February 2018, He has served as VP, head of the Rare Disease Division. Prior to that Matt was Sr. Director, Chief of Staff to the Global CEO Michel Vounatsos. He also worked in Payer and Channel Marketing for both the Rare Disease and MS Franchises while at Biogen. Matt worked in Life Science Consulting prior to coming to Biogen at a number of different companies. He worked on projects with small biotech as well as large pharmaceutical companies.